SIP has continuously demonstrated robust strength in underpinning development of new drugs, recording six Class 1 (first-in-class) innovative drugs approved for market launch so far this year, which account for about 20% of the total number of drugs of this kind approved in the country during this period.

Among these drugs is Ascentage Pharma’s Lisaftoclax for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in adults, and Suzhou Suncadia Biopharmaceuticals’ Trastuzumab Rezetecan for Injection for treatment of advanced non-small-cell lung cancer (NSCLC) with mutations in human epidermal growth factor 2 (HER2). The innovative drugs are expected to benefit a vast number of patients with cancers, metabolic disorders and other diseases.

SIP has been striving to concentrate resources for innovations in biomedical and health sectors since 2006, and so far has attracted more than 2,000 companies engaged in related fields, with the total output value reaching RMB165.5 billion last year.

July 23, 2025